References
- Buchanan KD, Johnston CF, O'Hare MM, et al. Neuroendocrine tumors: a European view. Am J Med 1986;81:14-22. https://doi.org/10.1016/0002-9343(86)90581-4
- Lam KY, Lo CY. Pancreatic endocrine tumour: a 22-year clinicopathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 1997;23:36-42. https://doi.org/10.1016/S0748-7983(97)80140-0
- Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010;21:1794-803. https://doi.org/10.1093/annonc/mdq022
- Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001;92:2204-10. https://doi.org/10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R
- Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:1-18. https://doi.org/10.1016/j.ecl.2010.12.005
- Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19: 1727-33. https://doi.org/10.1093/annonc/mdn351
- Cho MY, Kim JM, Sohn JH, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter study. Cancer Res Treat 2012;44:157-65. https://doi.org/10.4143/crt.2012.44.3.157
- Kulke MH, Benson AB 3rd, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw 2012;10:724-64. https://doi.org/10.6004/jnccn.2012.0075
- Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23. https://doi.org/10.1056/NEJM199202203260804
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
- Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology 2007; 85:216-20. https://doi.org/10.1159/000102969
- Torrisi JR, Treat J, Zeman R, Dritschilo A. Radiotherapy in the management of pancreatic islet cell tumors. Cancer 1987;60: 1226-31. https://doi.org/10.1002/1097-0142(19870915)60:6<1226::AID-CNCR2820600611>3.0.CO;2-7
- Rich TA. Radiation therapy for pancreatic cancer: eleven year experience at the JCRT. Int J Radiat Oncol Biol Phys 1985;11: 759-63. https://doi.org/10.1016/0360-3016(85)90308-6
- Saif MW, Ng J, Chang B, Russo S. Is there a role of radiotherapy in the management of pancreatic neuroendocrine tumors (PNET)? JOP 2012;13:174-6.
- Zagar TM, White RR, Willett CG, et al. Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:1126-31. https://doi.org/10.1016/j.ijrobp.2011.09.041
- Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078-85. https://doi.org/10.1067/msy.2001.118367
- Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62. https://doi.org/10.1200/JCO.2005.08.066
- Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23. https://doi.org/10.1056/NEJMoa1009290
- Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13. https://doi.org/10.1056/NEJMoa1003825
- Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24:3555-61. https://doi.org/10.1200/JCO.2006.05.6762
Cited by
- A case of pancreatic neuroendocrine tumors vol.5, pp.1, 2013, https://doi.org/10.1007/s13691-015-0230-x
- Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality? vol.15, pp.1, 2016, https://doi.org/10.1007/bf03401399
- Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors vol.47, pp.9, 2013, https://doi.org/10.1093/jjco/hyx081